Medicine Technology
| 7/3/2009 | FORT WORTH, Texas, July 3 In groundbreaking research, scientists at the University of North Texas Health Science Center at Fort Worth have determined that rapid estrogen administration can protect the brain following brain injury. These findings are now being tested on human trauma patients in North Texas. James Simpkins , Ph.D., UNT Health Science Ce... [Comments] |
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
| 7/3/2009 | TURKU, Finland, July 3 BioCis Pharma Ltd., a privatelyheld drug development company with its headquarters in Turku, Finland,announced positive results from its Phase IIa clinical trial of ProtoCure(TM)emulsion cream, the company's novel topical drug for dermatology. Thisdouble-blind, placebo-controlled study, conducted in Finland, included 13patients with mild t... [Comments] |
| 7/2/2009 | LEUVEN, Belgium and LUND, Sweden, July 3 ThromboGenics NV (Euronext Brussels: THR) and co-development partnerBioInvent International (OMXS: BINV) announce that they have startedrecruitment of a second cohort of patients for their Phase II trial ofTB-402. This follows completion of recruitment of the first cohort of 100patients ahead of schedule. TB-402... [Comments] |
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
| 7/2/2009 | PALATINE, Ill. and BRISTOL, Tenn., July 2 Acura Pharmaceuticals, Inc. (Nasdaq: ACUR ) and King Pharmaceuticals, Inc. (NYSE: KG ) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product i... [Comments] |
| 7/2/2009 | TOKYO and WOODCLIFF LAKE, N.J., July 2 Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further c... [Comments] |
deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia
| 7/1/2009 | REYKJAVIK, Iceland, July 1 The largest study ofthe genetics of schizophrenia ever undertaken has revealed several new commonsingle-letter variants in the sequence of the human genome (SNPs) linked torisk of the disease. The study, by a multinational consortium of scientistsled by a team from deCODE genetics (Nasdaq: DCGN ), analyzed the genomes ofmore... [Comments] |
New Review on PROSTVAC(TM) Published by Key Investigators From NCI
| 7/1/2009 | KVISTGAARD, Denmark, July 1 A just publishedReview in the publication "Expert Opinion on Investigational Drugs", Volume18, Issue 7 2009, confirms the previous published information onPROSTVAC(TM). This is the most comprehensive and updated Review onPROSTVAC(TM) so far. Quote from the article: "Preliminary clinical trials have indicatednegligib... [Comments] |
Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.
| 6/30/2009 | GLENDALE, Calif., June 30 If you have been eating Garlic to keep the mosquitoes away you may want to think again. While there is absolutely no scientific evidence that eating garlic actually keeps mosquitoes away, spraying garlic has plenty of evidence to prove it keeps them away. Spraying garlic extract on grassy lawns is not as strange as it seems. Mosquito Barrier... [Comments] |
PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
| 6/30/2009 | MIDLOTHIAN, Va., June 30 In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function. "We are pleased that researchers chose PARI products as the exclusive nebulizer systems for recent studies compa... [Comments] |
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
| 6/30/2009 | SAN DIEGO, June 30 Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS ( G auging R esponsiveness with A V erifyNow(R) Assay I mpact on T hrombosis A nd S afety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for pat... [Comments] |
(Date:7/2/2009)...t Principles to Govern Health Insurer Behavior , ...ire/ -- Nearly nine out of ten voters (88%) believ...fluence over how doctors care for their patients a...pt of a "Health Insurer Code of Conduct" that woul...h insurance companies with respect to how they dea...
(Date:7/2/2009).../ -- Dr Daniel Goldberg, a leading New Jersey opht... the effectiveness of using 5% Betadine irrigation..., highly contagious and often severe form of conju...impairment due to corneal involvement. , , Opht...ter to participate in the Betadine for EKC study. ...
(Date:7/2/2009)...ngsters with the disease , , THURSDAY, J...betes are more likely to be overweight than those ...ous health complications, researchers say. , Th...weight problems faced by U.S. youngsters with type...t usually shows up in childhood or in young adults...
(Date:7/2/2009)...y night saw the launch of (RED)ZONES at the first ...d off their new tour to a rapturous sold out crowd...tion areas directly adjacent to the stage which wi... for the (RED)ZONES are available through auction ...to the Global Fund to help fund AIDS programs in A...
Breaking Medicine News(10 mins):Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3...'s Hospital Boston say that they have found a new ... generally known that newborns// are at risk for d...stems have not been fully developed. In a study p...urnal Blood on April 25, Ofer Levy, MD, PhD and co...
...n Britain have said that The World Bank did not ai...to keep up the promised sum of $500 million// to c...ve manipulated data, with no adequate infrastructu...such a magnitude, reach completion. It is also bel...
...ies have declared that they will be launching a ma... infant and child deaths. This emergency vaccinati... aims to protect nearly thousands of children who ...d five years. Nearly 1,600 cases of measles have ...
...ne on 179 stroke patients, it was found that tripl...age when they had stroke. The three drug// a clot-...for blood pressure control, and a cholesterol-lowe...ynergistically to reduce the amount of brain tissu...
Other Medicine News:Health News:Enhancing Infants Immune System 2Health News:Enhancing Infants Immune System 3...he Integre Duo is the first solid-state,photocoa...en wavelengths. This advanced,laser system makes... green wavelength,during retina treatments, whic...ive,patient results., For common procedures li...
...he new Propaq LT is the perfect monitor for today'...ning the basic parameters of continuous vital sign...gn, making it perfect for just about any applicati... clip on an IV pole, small enough to carry around,...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly.
...ata Trol™ Abnormal Control Serum is intended...only used clinical chemistry assays. It is for in ...lyophilized format, the control offers up to ten d...e control is to be used in accordance with the dir...
Medicine Products:(Date:6/28/2009)...stCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SG... has been achieved in its Research and License Agr... of the Roche Group, for the generation of cell li...protein production purposes using Sangamo,s propri...N) technology. Genentech scientists demonstrated t...
(Date:6/28/2009)...9 , - Study Triggers $7.5m ... Corporation ("Sosei"; TSE Mothers Index: 4565) an...e the commencement of a Phase III,clinical study ...g muscarinic,antagonist (LAMA) for the treatment ...NVA237 is a dry powder formulation for oral inhala...
(Date:6/26/2009)...rstCall/ -- Sanofi-aventis (EURONEXT: SAN and NY...iated with a retrospective follow-up of four patie...how that no definitive conclusions can be drawn re...tus(R) (insulin glargine [rDNA] injection) use and... the study point out. , , Clinical studies, whi...
(Date:6/26/2009)...c Mutations Acting Together-- , , PHILADELPHIA,... the complex autism inheritance puzzle are emergin...ng geneticists from The Children,s Hospital of Phi... of Medicine and several collaborating institution...ons where rare copy number variations - missing or...
Breaking Medicine Technology:Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 1Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 2Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 3Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions 12489 1Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions 12489 2Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions 12489 3Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis 4540 1Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis 4540 2Genaera Corporation Announces Results of Special Meeting of Stockholders 48070 1Genaera Corporation Announces Results of Special Meeting of Stockholders 48070 2...Inflammatory Activity Demonstrated Among Patients ..., 2007 /PRNewswire/ --,ChemoCentryx, Inc., a clini...covering, developing and commercializing,orally-ad...system,presented data today from the company,s Ph... orally-active anti-inflammatory agent,that target...
...e Results from Phase 1 Studies with Monoclonal Ant...Data Provide Further,Rationale for IL-9 Inhibition...SBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ --...of data,highlighting recent progress within the co...esults from two Phase 1 clinical,studies with its ...
Other Medicine Technology:ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |